Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion
FDA Filing Anticipated In Early 2021
The results are in for hATTR amyloidosis with polyneuropathy, while results for hereditary and wild-type ATTR with cardiomyopathy are expected later this year.
